178 patents
Utility
Degradable Clostridial Toxins
18 Jan 24
The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
Lance E. Steward, Sanjiv Ghanshani, Ester Femandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
Filed: 23 Sep 22
Utility
In Vivo Synthesis of Elastic Fiber
4 Jan 24
Disclosed herein are methods of restoring elasticity in tissue using tropoelastin containing compositions.
Suzanne Marie MITHIEUX, Anthony Steven WEISS
Filed: 14 Jul 23
Utility
Treatment of migraine
2 Jan 24
The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant.
Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
Filed: 16 Jun 23
Utility
Ophthalmic Compositions and Methods for Treating Eyes
21 Dec 23
Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
Filed: 21 Mar 23
Utility
Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
19 Dec 23
Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes.
Jacob F. Pollock, Lauren E. Kokai, Cunqi Cui, Xiaojie Yu, Dennis E. Van Epps, Darin J. Messina
Filed: 31 Jul 19
Utility
Delayed Release Compositions of Linaclotide
14 Dec 23
The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Angelika Fretzen, Mark G. Currie, Ahmad Hashash, Mahendra Dedhiya, Yun Mo, Anil Chhettry, Matthew Miller, Ritesh Sanghvi, Mohammad Mafruhul Bari, Andreas Grill
Filed: 28 Aug 23
Utility
Time Released Biodegradable or Bioerodible Microspheres or Microparticles Suspended In a Solidifying Depot-forming Injectable Drug Formulation
7 Dec 23
A composite drug delivery material may be injected into an eye of a human being or mammal to provide sustained delivery of the drug.
David A. Marsh, Hongwen M. Rivers
Filed: 27 Dec 22
Utility
Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
5 Dec 23
Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers.
Xiaojie Yu, Nicholas J. Manesis, Jacob Pollock
Filed: 8 Oct 19
Utility
Implant Identification by Radiographic Means
30 Nov 23
A breast implant includes a flexible shell having an anterior face including an outer surface and an inner surface, and a marker attached to the inner surface of the anterior face of the shell.
David J. Schuessler, Alberto Flores-Pujol, Daniela Rodriguez-Estrada
Filed: 21 Apr 23
Utility
Injection paradigm for administration of botulinum toxins
21 Nov 23
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache.
Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin, David W. Dodick
Filed: 14 Jun 21
Utility
Non-protein Clostridial Toxin Compositions
9 Nov 23
Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described.
Maurice Abiad, Bhas Dani, Evgenyi Shalaev
Filed: 18 Apr 23
Utility
Non-protein Clostridial Toxin Compositions
9 Nov 23
Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described.
Maurice Abiad, Bhas Dani, Evgenyi Shalaev
Filed: 18 Apr 23
Utility
Stable Formulations of Linaclotide
2 Nov 23
The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Yun Mo, Angelika Fretzen, Brian Cali, Mahendra Dedhiya
Filed: 7 Jul 23
Utility
Digestive Enzyme Composition Suitable for Enteral Administration
26 Oct 23
The present invention is directed to a digestive enzyme composition comprising an enterically coated digestive enzyme product, administrable nutritional medium, and a pharmaceutically acceptable low viscosity oily ingredient.
Devrim EREN, Ruth THIEROFF-EKERDT, Luigi BOLTRI, Vincenza PIRONTI, Letizia UBIGLIA
Filed: 27 Jun 23
Utility
CorrectedTissue Expansion Device
19 Oct 23
A tissue expansion device can be implanted temporarily beneath skin of a patient and removed upon expansion of overlying tissue.
David J. Schuessler, Alberto J. Flores, Daniela Rodriguez, Luis M. Solano
Filed: 29 Oct 21
Utility
Treatment of Migraine
19 Oct 23
The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant.
Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
Filed: 16 Jun 23
Utility
Methods and Compositions for Topical Delivery of Prostaglandins to Subcutaneous Fat
19 Oct 23
Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid, e.g., oleic acid, that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound or active metabolite thereof to subcutaneous fat under the skin.
Michael S. Singer, Murat V. Kalayoglu
Filed: 31 Jan 23
Utility
Botulinum Neurotoxin Proteins and Methods to Engineer and Generate Same
19 Oct 23
Botulinum neurotoxin proteins and fragments thereof that bind and/or cleave a noncanonical substrate, e.g., non-neuronal SNARE proteins such as human SNAP-23 (hSNAP-23) and SNAP-29 (hSNAP-29), are described.
Gregory A. Weiss, Amy D. Brideau-Andersen, Rebekah P. Dyer, Lance E. Steward, Linh Q. Le, Gaetano Speciale, David C. Rupp, Birgitte P.S. Jacky, Madison H. Fletcher, Sudipta Majumdar
Filed: 24 Aug 21
Utility
Microneedle Array with Active Ingredient
12 Oct 23
Microneedle arrays for introducing an active ingredient through a skin surface of a patient can include a base layer, a plurality of microneedles projecting from the base layer, and a shell layer having an active ingredient.
Futian LIU, Xiaojie YU, Lance E. STEWARD
Filed: 14 Dec 22
Utility
Cells Useful for Immuno-based Botulinum Toxin Serotype a Activity Assays
12 Oct 23
The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
Hong Zhu, Joanne Wang, Birgitte P. Jacky, D. Dianne Hodges, Ester Fernandez-Salas
Filed: 9 Aug 22